Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort
Authors:
- Manuel F. Ugarte-GilMUManuel F. Ugarte-Gil
- Daniel WojdylaDWDaniel Wojdyla
- Guillermo J. Pons-EstelGPGuillermo J. Pons-Estel
- Rosana QuintanaRQRosana Quintana
- José A. Gómez-PuertaJGJosé A. Gómez-Puerta
- Luis J. CatoggioLCLuis J. Catoggio
- Alejandro AlvarellosAAAlejandro Alvarellos
- Verónica SauritVSVerónica Saurit
- Eduardo BorbaEBEduardo Borba
- Emilia SatoESEmilia Sato
- Lilian CostallatLCLilian Costallat
- Nilzio A. Da SilvaNSNilzio A. Da Silva
- 1 March 2019
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 46 (10) , 1299-1308
Abstract
Objective.: To determine the predictors of remission and low disease activity state (LDAS) in patients with systemic lupus erythematosus (SLE). Methods.: Three disease activity states were defined: Remission = SLE Disease Activity Index (SLEDAI) = 0 and prednisone ≤ 5 mg/day and/or immunosuppressants (maintenance dose); LDAS = SLEDAI ≤ 4, prednisone ≤ 7.5 mg/day and/or immunosuppressants (maintenance dose); and non-optimally controlled state = SLEDAI > 4 and/or prednisone > 7.5 mg/day and/or immunosuppressants (induction dose). Antimalarials were allowed in all groups. Patients with at least 2 SLEDAI reported and not optimally controlled at entry were included in these analyses. Outcomes were remission and LDAS. Multivariable Cox regression models (stepwise selection procedure) were performed for remission and for LDAS. Results.: Of 1480 patients, 902 were non-optimally controlled at entry; among them, 196 patients achieved remission (21.7%) and 314 achieved LDAS (34.8%). Variables predictive of a higher probability of remission were the absence of mucocutaneous manifestations (HR 1.571, 95% CI 1.064–2.320), absence of renal involvement (HR 1.487, 95% CI 1.067–2.073), and absence of hematologic involvement (HR 1.354, 95% CI 1.005–1.825); the use of immunosuppressive drugs before the baseline visit (HR 1.468, 95% CI 1.025–2.105); and a lower SLEDAI score at entry (HR 1.028, 95% CI 1.006–1.051 per 1-unit decrease). These variables were predictive of LDAS: older age at entry, per 5-year increase (HR 1.050, 95% CI 1.004–1.098); absence of mucocutaneous manifestations (HR 1.401, 95% CI 1.016–1.930) and renal involvement (HR 1.344, 95% CI 1.049–1.721); and lower SLEDAI score at entry (HR 1.025, 95% CI 1.009–1.042). Conclusion.: Absence of mucocutaneous, renal, and hematologic involvement, use of immunosuppressive drugs, and lower disease activity early in the course of the disease were predictive of remission in patients with SLE; older age was predictive of LDAS.Keywords
This publication has 20 references indexed in Scilit:
- Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remissionAnnals of the Rheumatic Diseases, 2018
- Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL)Annals of the Rheumatic Diseases, 2017
- A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)Annals of the Rheumatic Diseases, 2017
- Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosusRheumatology, 2016
- Defining Low Disease Activity in Systemic Lupus ErythematosusArthritis Care & Research, 2016
- Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)Annals of the Rheumatic Diseases, 2016
- Treat to target in systemic lupus erythematosus: a commentaryClinical Rheumatology, 2016
- Prolonged remission in Caucasian patients with SLE: prevalence and outcomesAnnals of the Rheumatic Diseases, 2015
- Prolonged Clinical Remission in Patients with Systemic Lupus ErythematosusThe Journal of Rheumatology, 2014
- Treat-to-target in systemic lupus erythematosus: recommendations from an international task forceAnnals of the Rheumatic Diseases, 2014